

## **Arrivo Bio Promotes Kelly Abernathy to Chief Operating Officer**

MORRISVILLE, N.C., February 3, 2026 – [Arrivo Bio](#) announced today the promotion of Kelly Abernathy to Chief Operating Officer. Kelly previously served as Vice President of Clinical Development, where she worked across the company's clinical programs including RABI-767, targeting severe acute pancreatitis, and Forvisirvat, in development for major depressive disorder.

Kelly's leadership in clinical trial design and execution has significantly contributed to the advancement of the Arrivo portfolio. In her new role, Kelly will have broad operational responsibilities as the company is preparing for the completion of the Phase 2b/3 study of Forvisirvat in patients with major depressive disorder in mid-2026 and aims to take the final steps toward an NDA submission.

Her promotion underscores her proven ability to drive operational excellence and advance Arrivo Bio's mission of developing first-of-its-kind medicines for hard-to-treat diseases.

### **About Arrivo Bio**

Arrivo is developing first-of-its-kind medicines that target the root cause of hard-to-treat diseases with the goal of achieving meaningful outcomes for patients, allowing them to live longer, healthier lives. Arrivo has two clinical-stage pipeline candidates, Forvisirvat (SP-624) for major depressive disorder and RABI-767 for predicted severe acute pancreatitis. Arrivo is based in Morrisville, N.C., on the edge of Research Triangle Park. For more information, visit [www.arrivobio.com](http://www.arrivobio.com).

### **Media Contact:**

Alexis Feinberg

Vice President, ICR Healthcare

[Alexis.feinberg@icrhealthcare.com](mailto:Alexis.feinberg@icrhealthcare.com)